Joel Ackerman
Management
Good afternoon, I’m Joel Ackerman the CEO of Champions Oncology. Thank you for joining us for our quarterly earnings call. After a brief introduction I will cover the highlights since our last call, talk about the financial results and then open it up to questions. Before I start I will remind you that I will make forward-looking statements during the call and actual results could differ materially from what is described in those statements. Also additional information on factors that could cause results to differ is available in our Form 10Q and 10K, reconciliation of these non-GAAP financial measures that maybe discussed on the call to GAAP financial measures is available in the earnings release. We currently anticipate that our 10K for fiscal year ending April 30, 2014 will be filed on Monday July 28th. Our fiscal fourth quarter which ended in April was the culmination of the Europe’s great progress for Champions. As I step back and look at the company today versus where we were 3.5 years ago when Ronnie Morris and I took over the leadership of the company, it's remarkable how far we have come. We started with eight employees, $3 million of core revenue and limited experience with our TumorGraft technology platform. Over these years we have grown the company to 65 employees almost $12 million in revenue and have proven to ourselves and others the value of our platform. From the new senior managers who choose to join Champions to the deals we have signed with Pfizer and Mount Sinai to the papers and posters that have demonstrated the predictivity in value of TumorGraft’s or proud of the validation we have generated about our technology and business model. As a result of all this, we believe we’re nearing the end of the proof of…